The Intestinal Epithelial Insulin-Like Growth Factor-1 Receptor Links Glucagon-Like Peptide-2 Action to Gut Barrier Function
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-2 (GLP-2) is an intestinal growth-promoting hormone used to treat short bowel syndrome. GLP-2 promotes intestinal growth through a mechanism that involves both IGF-1 and the intestinal-epithelial IGF-1 receptor (IE-IGF-1R). GLP-2 also enhances intestinal barrier function, but through an unknown mechanism. We therefore hypothesized that GLP-2-enhanced barrier function requires the IE-IGF-1R and is mediated through alterations in expression and localization of tight junction proteins. Conditional IE-IGF-1R-null and control mice were treated with vehicle or degradation-resistant Gly(2)-GLP-2 for 10 days; some animals also received irinotecan to induce enteritis. Mice were then examined for gastrointestinal permeability to 4-kDa fluorescein isothiocyanate-dextran, jejunal resistance using Ussing chambers, tight junction structure by electron microscopy, and expression and localization of tight junction proteins by immunoblot and immunohistofluorescence, respectively. GLP-2 treatment decreased permeability to 4-kDa fluorescein isothiocyanate-dextran and increased jejunal resistance (P <.05-.01), effects that were lost in IE-IGF-1R-null mice. Electron microscopy did not reveal major structural changes in the tight junctions in any group of animals. However, the tight junctional proteins claudin-3 and -7 were upregulated by GLP-2 in control (P <.05-.01) but not null mice, whereas IE-IGF-1R deletion induced a shift in occludin localization from apical to intracellular domains; no changes were observed in expression or distribution of claudin-15 and zona occludins-1. Finally, in irinotecan-induced enteritis, GLP-2 normalized epithelial barrier function in control (P < .05) but not knockout animals. In conclusion, the effects of GLP-2 on intestinal barrier function are dependent on the IE-IGF-1R and involve modulation of key components of the tight junctional complex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518
Crosstalk of tight junction components with signaling pathways
González-Mariscal, L., Tapia, R., & Chamorro, D. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.08.018 · Cited by 759 · cited 2×
“Because the present study is the first to our knowledge that implicates IGF signaling as a direct regulator of intestinal tight junction protein expression (claudin-3 and -7) and localization (occludin), additional studies will be required to determine through which downstream signaling pathway these effects are media…”
BackgroundGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 1×
“To develop a model of altered barrier function, control and KO animals were first subjected to multiple low-dose injections of streptozotocin, using a protocol known to induce diabetes in normal C57BL/6 mice (27).”
MethodUpregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
Cheeseman, C. I. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.273.6.r1965 · Cited by 267
Cited by
Gart, E., Souto Lima, E., Schuren, F., De Ruiter, C. G. F., Attema, J., Verschuren, L., Keijer, J., Salic, K., Morrison, M. C., & Kleemann, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010001 · Cited by 1,093
Gut barrier disruption and chronic disease
Martel, J., Chang, S.-H., Ko, Y.-F., Hwang, T.-L., Young, J. D., & Ojcius, D. M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.01.002 · Cited by 514
Regulation of Obesity-Related Insulin Resistance with Gut Anti-inflammatory Agents
Luck, H., Tsai, S., Chung, J., Clemente-Casares, X., Ghazarian, M., Revelo, X. S., Lei, H., Luk, C. T., Shi, S. Y., Surendra, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.001 · Cited by 368
Tight junction proteins in gastrointestinal and liver disease
Zeisel, M. B., Dhawan, P., & Baumert, T. F. (2019) · Gut · doi:10.1136/gutjnl-2018-316906 · Cited by 358
Worthington, J. J., Reimann, F., & Gribble, F. M. (2018) · Mucosal Immunology · doi:10.1038/mi.2017.73 · Cited by 262
Metadata
- Authors
- Dong, C. X., Zhao, W., Solomon, C., Rowland, K. J., Ackerley, C., Robine, S., Holzenberger, M., Gonska, T., & Brubaker, P. L.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-02-01
- Volume
- 155
- Issue
- 2
- Pages
- 370-379
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2007410107
- Cited by
- 108
- References
- 4
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Intestinal Epithelial Insulin-Like Growth Factor-1 Receptor Links Glucagon-Like Peptide-2 Action to Gut Barrier Function. https://app.cochat.ai/papers/10.1210/en.2013-1871
- The paper
- Dong, C. X., Zhao, W., Solomon, C., Rowland, K. J., Ackerley, C., Robine, S., Holzenberger, M., Gonska, T., & Brubaker, P. L. (2014). The Intestinal Epithelial Insulin-Like Growth Factor-1 Receptor Links Glucagon-Like Peptide-2 Action to Gut Barrier Function. Endocrinology. https://doi.org/10.1210/en.2013-1871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.